Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1995 Aug;85(4):668–674.

Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

S Stephens 1, S Emtage 1, O Vetterlein 1, L Chaplin 1, C Bebbington 1, A Nesbitt 1, M Sopwith 1, D Athwal 1, C Novak 1, M Bodmer 1
PMCID: PMC1383798  PMID: 7558164

Abstract

A murine antibody to human tumour necrosis factor-alpha (TNF-alpha) (CB0010) was complementarity-determining region (CDR)-grafted using human IgG4 heavy and kappa light chain constant regions. In cynomolgus monkeys, the grafted antibody (CDP571) was eliminated with a half-life of 40-90 hr, two to three times longer than CB0010, and immunogenicity was reduced by > 90%. Responses to the constant regions were almost entirely eliminated and responses to the CDR loop (anti-idiotype) were lowered. CDP571 was given to 24 human volunteers in doses from 0.1 to 10.0 mg/kg. It was well tolerated, with a half-life of approximately 13 days. Anti-CDP571 antibodies were low or undetectable at higher doses. At lower doses, anti-CDP571 peaked at 2 weeks and then declined. The response was primarily IgM (in contrast to the cynomolgus monkey, where by 5 weeks IgG predominated) and was against a conformational epitope comprising heavy and light chain CDR loops. No antibodies were detected against the gamma 4/kappa domains or frameworks. The response had little or no effect on CDP571 binding to TNF-alpha or on plasma clearance.

Full text

PDF
668

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brennan F. M., Gibbons D. L., Mitchell T., Cope A. P., Maini R. N., Feldmann M. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol. 1992 Jul;22(7):1907–1912. doi: 10.1002/eji.1830220734. [DOI] [PubMed] [Google Scholar]
  2. Brüggemann M., Winter G., Waldmann H., Neuberger M. S. The immunogenicity of chimeric antibodies. J Exp Med. 1989 Dec 1;170(6):2153–2157. doi: 10.1084/jem.170.6.2153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Daugherty B. L., DeMartino J. A., Law M. F., Kawka D. W., Singer I. I., Mark G. E. Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res. 1991 May 11;19(9):2471–2476. doi: 10.1093/nar/19.9.2471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Exley A. R., Cohen J., Buurman W., Owen R., Hanson G., Lumley J., Aulakh J. M., Bodmer M., Riddell A., Stephens S. Monoclonal antibody to TNF in severe septic shock. Lancet. 1990 May 26;335(8700):1275–1277. doi: 10.1016/0140-6736(90)91337-a. [DOI] [PubMed] [Google Scholar]
  5. Greenberg R. N., Wilson K. M., Kunz A. Y., Wedel N. I., Gorelick K. J. Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis. Crit Care Med. 1992 Jun;20(6):730–735. doi: 10.1097/00003246-199206000-00005. [DOI] [PubMed] [Google Scholar]
  6. Hakimi J., Chizzonite R., Luke D. R., Familletti P. C., Bailon P., Kondas J. A., Pilson R. S., Lin P., Weber D. V., Spence C. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol. 1991 Aug 15;147(4):1352–1359. [PubMed] [Google Scholar]
  7. Hale G., Dyer M. J., Clark M. R., Phillips J. M., Marcus R., Riechmann L., Winter G., Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988 Dec 17;2(8625):1394–1399. doi: 10.1016/s0140-6736(88)90588-0. [DOI] [PubMed] [Google Scholar]
  8. Imagawa D. K., Millis J. M., Seu P., Olthoff K. M., Hart J., Wasef E., Dempsey R. A., Stephens S., Busuttil R. W. The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation. 1991 Jan;51(1):57–62. doi: 10.1097/00007890-199101000-00008. [DOI] [PubMed] [Google Scholar]
  9. Isaacs J. D., Watts R. A., Hazleman B. L., Hale G., Keogan M. T., Cobbold S. P., Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992 Sep 26;340(8822):748–752. doi: 10.1016/0140-6736(92)92294-p. [DOI] [PubMed] [Google Scholar]
  10. Jones P. T., Dear P. H., Foote J., Neuberger M. S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. 1986 May 29-Jun 4Nature. 321(6069):522–525. doi: 10.1038/321522a0. [DOI] [PubMed] [Google Scholar]
  11. Khazaeli M. B., Saleh M. N., Liu T. P., Meredith R. F., Wheeler R. H., Baker T. S., King D., Secher D., Allen L., Rogers K. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res. 1991 Oct 15;51(20):5461–5466. [PubMed] [Google Scholar]
  12. Khazaeli M. B., Saleh M. N., Wheeler R. H., Huster W. J., Holden H., Carrano R., LoBuglio A. F. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst. 1988 Aug 17;80(12):937–942. doi: 10.1093/jnci/80.12.937. [DOI] [PubMed] [Google Scholar]
  13. LoBuglio A. F., Wheeler R. H., Trang J., Haynes A., Rogers K., Harvey E. B., Sun L., Ghrayeb J., Khazaeli M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220–4224. doi: 10.1073/pnas.86.11.4220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mitchison N. A. The dosage requirements for immunological paralysis by soluble proteins. Immunology. 1968 Oct;15(4):509–530. [PMC free article] [PubMed] [Google Scholar]
  15. Morrison S. L., Johnson M. J., Herzenberg L. A., Oi V. T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851–6855. doi: 10.1073/pnas.81.21.6851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mountain A., Adair J. R. Engineering antibodies for therapy. Biotechnol Genet Eng Rev. 1992;10:1–142. doi: 10.1080/02648725.1992.10647886. [DOI] [PubMed] [Google Scholar]
  17. Nicholls S., Stephens S., Braegger C. P., Walker-Smith J. A., MacDonald T. T. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol. 1993 Aug;46(8):757–760. doi: 10.1136/jcp.46.8.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Padlan E. A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol. 1991 Apr-May;28(4-5):489–498. doi: 10.1016/0161-5890(91)90163-e. [DOI] [PubMed] [Google Scholar]
  19. Riethmüller G., Schneider-Gädicke E., Schlimok G., Schmiegel W., Raab R., Höffken K., Gruber R., Pichlmaier H., Hirche H., Pichlmayr R. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994 May 14;343(8907):1177–1183. doi: 10.1016/s0140-6736(94)92398-1. [DOI] [PubMed] [Google Scholar]
  20. Sears H. F., Bägli D. J., Herlyn D., DeFreitas E., Suzuki H., Steele G., Koprowski H. Human immune response to monoclonal antibody administration is dose-dependent. Arch Surg. 1987 Dec;122(12):1384–1388. doi: 10.1001/archsurg.1987.01400240030004. [DOI] [PubMed] [Google Scholar]
  21. Sharief M. K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med. 1991 Aug 15;325(7):467–472. doi: 10.1056/NEJM199108153250704. [DOI] [PubMed] [Google Scholar]
  22. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES